# A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

> **NCT03104400** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 1705 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** Upadacitinib
- **DRUG:** Placebo to Upadacitinib
- **DRUG:** Placebo to Adalimumab

## Key facts

- **NCT ID:** NCT03104400
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-27
- **Primary completion:** 2019-09-26
- **Final completion:** 2024-09-09
- **Target enrollment:** 1705 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03104400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03104400, "A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03104400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*